Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis

Abstract

Background: Immune checkpoint inhibitors (ICIs) can lead to one of the common and quite serious immune-related adverse events (irAEs) in a real-world setting, namely, checkpoint inhibitor pneumonitis (CIP). Objective: We aimed to investigate the potential risk factors for CIP in cancer patients treated by ICIs and quantify the association. Methods: We conducted a systematic literature review in PubMed, EMBASE, and Web of Science from January 1, 2000, to March 20, 2022, with no study design restrictions. Studies evaluating the risk factors for CIP in cancer patients treated with ICIs-containing regimes were included. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for risk factors of CIP by using random-effect model. Heterogeneity was assessed by sensitivity analysis and subgroup analysis regarding CIP severity, geographical regions, cancer types, treatment regimes, and ICI types. Results: A total of 35 studies comprising 142,703 patients were eventually included. The incidence of grade I–V and grade III–V CIP in cancer patients was 0.16 (95% CI: 0.14–0.18) and 0.06 (95% CI: 0.05–0.08), respectively. When combining the adjusted ORs, the following risk factors were significantly associated with the development of CIP: squamous cell carcinoma (OR: 1.31, 95% CI: 1.18–1.45), previous thoracic radiotherapy (OR: 2.07, 95% CI: 1.34–3.19), preexisting radiation-induced pneumonitis (OR: 3.62, 95% CI: 1.53–8.58), preexisting respiratory disease (OR: 2.43, 95% CI: 1.45–4.07), preexisting interstitial lung disease (OR: 5.78, 95% CI: 3.08–10.85), preexisting ground glass attenuation (OR: 11.48, 95% CI: 1.13–116.74), preexisting honeycombing (OR: 6.11, 95% CI: 2.37–15.79), preexisting pulmonary emphysema (OR: 2.72, 95% CI: 1.00–7.36), use of pembrolizumab (OR: 2.89, 95% CI: 1.56–5.35, I2 = 0%), high PD-L1 expression (OR: 3.59, 95% CI: 1.23–10.50), and hypoalbuminemia (OR: 0.3, 95% CI: 0.14–0.64). When including the crude ORs, smoking history (OR: 1.39, 95% CI: 1.14–1.71), neutrophil-lymphocyte ratio (OR: 1.04, 95% CI: 1.01–1.08), and c-reactive protein (OR: 1.08, 95% CI: 1.01–1.16) were also risk factors for CIP. Conclusion: Histological characteristics, specific previous lung diseases and treatment history, treatment regimen, PD-L1 expression level, and serological biomarkers are all closely associated with the development of CIP. These findings would be useful for oncologists to optimize the appropriate options of ICIs and close monitoring during immunotherapy treatments, particularly for patients identified as having a higher risk for CIP.

© 2022 S. Karger AG, Basel

References Anagnostou VK, Brahmer JR. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res. 2015;21(5):976–84. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35. Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018;29(4):959–65. Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):723–33. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–18. Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377–85. Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, et al. Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer. JAMA Oncol. 2020;6(12):1952–6. Zhang M, Fan Y, Nie L, Wang G, Sun K, Cheng Y. Clinical outcomes of immune checkpoint inhibitor therapy in patients with advanced non-small cell lung cancer and preexisting interstitial lung diseases: a systematic review and meta-analysis. Chest. 2022;161(6):1675–86. Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13(8):473–86. Liu T, Jin B, Chen J, Wang H, Lin S, Dang J, et al. Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis. Ther Adv Med Oncol. 2020;12:1758835920940927. Wang DY, Salem J-E, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–8. Suresh K, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, et al. Pneumonitis in non–small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol. 2018;13(12):1930–9. Suazo-Zepeda E, Bokern M, Vinke PC, Hiltermann TJN, de Bock GH, Sidorenkov G. Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Cancer Immunol Immunother. 2021;70(11):3069–80. Fujiwara Y, Horita N, Namkoong H, Galsky MD. The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials. Eur J Cancer. 2021;150:168–78. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280–6. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. Scottish Intercollegiate Guidelines Network (SIGN). https://wwwsignacuk/. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. Yamaguchi T, Shimizu J, Oya Y, Watanabe N, Hasegawa T, Horio Y, et al. Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: a retrospective analysis. Thorac Cancer. 2022;13(5):724–31. Wang H, Zhou F, Zhao C, Cheng L, Zhou C, Qiao M, et al. Interleukin-10 is a promising marker for immune-related adverse events in patients with non-small cell lung cancer receiving immunotherapy. Front Immunol. 2022;13:840313. Chao Y, Zhou J, Hsu S, Ding N, Li J, Zhang Y, et al. Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer. Transl Lung Cancer Res. 2022;11(2):295–306. Yamamoto N, Nakanishi Y, Gemma A, Nakagawa K, Sakamoto T, Akamatsu A, et al. Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: postmarketing surveillance. Cancer Sci. 2021;112(11):4692–701. Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Hanai N, et al. Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis. BMC Cancer. 2021;21(1):924. Tyczynski JE, Potluri R, Kilpatrick R, Mazumder D, Ghosh A, Liede A. Incidence and risk factors of pneumonitis in patients with non-small cell lung cancer: an observational analysis of real-world data. Oncol Ther. 2021;9(2):471–88. Stahlbaum DE, Jablonski R, Strek ME, Reid P. Case control study assessing pulmonary risk factors for immune checkpoint inhibitor pneumonitis. Am J Respir Crit Care Med. 2021;203(9). Shimoji K, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, et al. MO10-2 Association of pre-existing interstitial lung abnormalities with immune checkpoint inhibitor-induced interstitial lung disease among patients with non-lung cancers. JAMA Netw Open. 2020;32(11):e2022906. Lin X, Deng H, Yang Y, Wu J, Qiu G, Li S, et al. Peripheral blood biomarkers for early diagnosis, severity, and prognosis of checkpoint inhibitor-related pneumonitis in patients with lung cancer. Front Oncol. 2021;11:698832. Jung J, Kim HY, Kim DG, Park SY, Ko AR, Han JY, et al. Sequential treatment with an immune checkpoint inhibitor followed by a small-molecule targeted agent increases drug-induced pneumonitis. Cancer Res Treat. 2021;53(1):77–86. Isono T, Kagiyama N, Takano K, Hosoda C, Nishida T, Kawate E, et al. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors. Thorac Cancer. 2021;12(2):153–64. Husain A, Siddiqi M, Patel S, Montgrain P, Akuthota P. Association between peak eosinophil counts and checkpoint-inhibitor pneumonitis in patients with advanced primary lung cancer. Chest. 2021;160(4):A1606–7. Chen Y, Liu X, Huang Z, Zhao K, Wang Y, Ren F, et al. Safety of thoracic radiotherapy after PD-(L)1 inhibitor treatment in patients with lung cancer. Cancer Med. 2021;10(23):8518–29. Atchley WT, Alvarez C, Saxena-Beem S, Schwartz TA, Ishizawar RC, Patel KP, et al. Immune checkpoint inhibitor-related pneumonitis in lung cancer real-world incidence, risk factors, and management practices across six health care centers in North Carolina. Chest. 2021;160(2):731–42. Asada M, Mikami T, Niimura T, Zamami Y, Uesawa Y, Chuma M, et al. The risk factors associated with immune checkpoint inhibitor-related pneumonitis. Oncology. 2021;99(4):256–9. Zhang C, Gao F, Jin S, Gao W, Chen S, Guo R. Checkpoint inhibitor pneumonitis in Chinese lung cancer patients: clinical characteristics and risk factors. Ann Palliat Med. 2020;9(6):3957–65. Suzuki Y, Karayama M, Uto T, Fujii M, Matsui T, Asada K, et al. Assessment of immune-related interstitial lung disease in patients with NSCLC treated with immune checkpoint inhibitors: a multicenter prospective study. J Thorac Oncol. 2020;15(8):1317–27. Sugano T, Seike M, Saito Y, Kashiwada T, Terasaki Y, Takano N, et al. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer. Thorac Cancer. 2020;11(4):1052–60. Okada N, Matsuoka R, Sakurada T, Goda M, Chuma M, Yagi K, et al. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study. Sci Rep. 2020;10(1):13773. Li M, Spakowicz D, Zhao S, Patel SH, Johns A, Grogan M, et al. Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer. Cancer Immunol Immunother. 2020;69(11):2403–8. Hata H, Mio T, Yamashita D, Matsumura C, Chisaki Y, Motohashi H, et al. Factors associated with efficacy and nivolumab-related interstitial pneumonia in non-small cell lung cancer: a retrospective survey. Cancer Control. 2020;27(4):1073274820977200. Chu X, Zhao J, Zhou J, Zhou F, Jiang T, Jiang S, et al. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. Lung Cancer. 2020;150:76–82. Barrón F, Sánchez R, Arroyo-Hernández M, Blanco C, Zatarain-Barrón ZL, Catalán R, et al. Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy. Front Oncol. 2020;10:570233. Sukari A, Nagasaka M, Alhasan R, Patel D, Wozniak A, Ramchandren R, et al. Cancer site and adverse events induced by immune checkpoint inhibitors: a retrospective analysis of real-life experience at a single institution. Anticancer Res. 2019;39(2):781–90. Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, et al. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer. Respir Investig. 2019;57(5):451–9. Moda M. Characteristics, incidence, risk factors, and practical management of pneumonitis associated with anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Eur Respir J. 2019;54:PA366. Mamesaya N, Narita SN, Naito T, Udagawa H, Goto K, Miyawaki T, et al. Nivolumab-induced and radiation recall pneumonitis in patients with non-small cell lung cancer: a multicenter real world analysis of 669 patients. Ann Oncol. 2019;30:v618. Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, Morise M, et al. Prognostic impact and risk factors of immune-related pneumonitis in patients with non–small-cell lung cancer who received programmed death 1 inhibitors. Clin Lung Cancer. 2019;20(6):442–50.e4. Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Yatabe Y, et al. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a retrospective analysis. Lung Cancer. 2018;125:212–7. Owen DH, Wei L, Bertino EM, Edd T, Villalona-Calero MA, He K, et al. Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer. Clin Lung Cancer. 2018;19(6):E893–900. Nakahama K, Tamiya A, Isa S-I, Taniguchi Y, Shiroyama T, Suzuki H, et al. Association between imaging findings of airway obstruction adjacent to lung tumors and the onset of interstitial lung disease after nivolumab. In Vivo. 2018;32(4):887–91. Komiya K, Nakamura T, Hirakawa H, Ogusu S, Nakashima C, Takahashi K, et al. P1.01-49 irAE, possible predictive markers for immune checkpoint inhibitors. J Thorac Oncol. 2018;13(10):S479–80. Cui P, Liu Z, Wang G, Ma J, Qian Y, Zhang F, et al. Risk factors for pneumonitis in solid tumors treated with anti-programmed death-1 therapy: a case-control study. J Clin Oncol. 2018;36(Suppl 15):e15132. Tamiya A, Tamiya M, Nakahama K, Taniguchi Y, Shiroyama T, Isa SI, et al. The efficacy and onset risk of interstitial lung disease of nivolumab in elderly (75 years old or older) patients with non-small cell lung cancer. Ann Oncol. 2017;28:x133. Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest. 2017;152(2):271–81. Cadranel J, Canellas A, Matton L, Darrason M, Parrot A, Naccache J-M, et al. Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. Eur Respir Rev. 2019;28(153):190058. Ando H, Suzuki K, Yanagihara T. Insights into potential pathogenesis and treatment options for immune-checkpoint inhibitor-related pneumonitis. Biomedicines. 2021;9(10):1484. Cho JY, Kim J, Lee JS, Kim YJ, Kim SH, Lee YJ, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. Lung Cancer. 2018;125:150–6. Filho MM, Aguiar PN, de Mello RA. Chronic obstructive pulmonary disease alters immune cell composition and immune checkpoint inhibitor efficacy in non-small cell lung cancer. Ann Transl Med. 2019;7(Suppl 1):S42. McKendry RT, Spalluto CM, Burke H, Nicholas B, Cellura D, Al-Shamkhani A, et al. Dysregulation of antiviral function of CD8(+) T cells in the chronic obstructive pulmonary disease lung. Role of the PD-1-PD-L1 axis. Am J Res Crit Care Med. 2016;193(6):642–51. Nakazawa M, Suzuki K, Takeshita M, Inamo J, Kamata H, Ishii M, et al. Distinct expression of coinhibitory molecules on alveolar T cells in patients with rheumatoid arthritis-associated and idiopathic inflammatory myopathy-associated interstitial lung disease. Arthritis Rheumatol. 2021;73(4):576–86. Suzuki K, Yanagihara T, Matsumoto K, Kusaba H, Yamauchi T, Ikematsu Y, et al. Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease. Int Immunol. 2020;32(8):547–57. Kenmotsu H, Naito T, Kimura M, Ono A, Shukuya T, Nakamura Y, et al. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol. 2011;6(7):1242–6. Tasaka Y, Honda T, Nishiyama N, Tsutsui T, Saito H, Watabe H, et al. Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease. Lung Cancer. 2021;155:120–6. Cousin F, Desir C, Ben Mustapha S, Mievis C, Coucke P, Hustinx R. Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer. Radiother Oncol. 2021;157:47–55. Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22(24):6051–60. Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895–903. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28. Zhai X, Zhang J, Tian Y, Li J, Jing W, Guo H, et al. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients. Cancer Biol Med. 2020;17(3):599–611. Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol. 2021;18(10):625–44. Iams WT, Porter J, Horn L. Immunotherapeutic approaches for small-cell lung cancer. Nat Rev Clin Oncol. 2020;17(5):300–12. Yan YD, Cui JJ, Fu J, Su YJ, Chen XY, Gu ZC, et al. A network comparison on safety profiling of immune checkpoint inhibitors in advanced lung cancer. Front Immunol. 2021;12:760737. Ma K, Lu Y, Jiang S, Tang J, Li X, Zhang Y. The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis. Front Pharmacol. 2018;9:1430. Su Q, Zhu EC, Wu J-B, Li T, Hou Y-L, Wang D-Y, et al. Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis. Front Immunol. 2019;10:108. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–301. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847–56. Article / Publication Details

First-Page Preview

Abstract of Systematic Review and Meta-Analysis

Received: May 03, 2022
Accepted: June 22, 2022
Published online: September 15, 2022

Number of Print Pages: 16
Number of Figures: 3
Number of Tables: 2

ISSN: 0025-7931 (Print)
eISSN: 1423-0356 (Online)

For additional information: https://www.karger.com/RES

留言 (0)

沒有登入
gif